clairop

Signs Your Ulcerative Colitis Is Healing

Bleeding usually settles first, then stool frequency, then calprotectin, then the lining. Here is the order, the timings and what feeling better can miss.

Clairop Team18 min read

Photo: The Ridge Ohio / Unsplash

The short answer

Ulcerative colitis improves in a fairly consistent order. Rectal bleeding usually settles first, stool frequency follows, inflammation markers such as calprotectin normalize next, and the colon lining looks healthy last. Feeling well is the first sign, not proof: in one study 45% of people in clinical remission still had inflammation on scope. Your IBD team confirms it with tests.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

If you are searching for signs that your ulcerative colitis is healing, you are probably somewhere in the middle of a flare, hoping the last few days really were better. The honest answer has two halves. The first half is reassuring: ulcerative colitis tends to improve in a fairly predictable order, and you can feel the early steps. The second half is the part most pages skip: feeling better is the first sign of healing, not the proof of it, because the lining of the colon can still be inflamed when you have no symptoms at all.

This guide is built around the questions people actually type into Google about this, answered in the order that makes the picture clearest. It does not give medication advice, and it does not replace your IBD team. What it does is explain what clinicians look for, in what order, and how to tell the difference between "I feel better" and "my colon has calmed down".

What are the signs that ulcerative colitis is healing?

The signs you can notice yourself are less visible blood in the stool, fewer bowel movements per day, easing urgency, fewer night-time trips and returning energy. The signs your clinicians look for are normal blood and stool inflammation markers, then a healthy-looking lining on endoscopy. The first group arrives first; the second group is what confirms it.

Here is what that looks like in practice, roughly in the order most people notice.

Blood fades. Rectal bleeding is the symptom most tightly tied to active inflammation in the rectum, and it is usually the first to ease. Streaks become occasional, then stop.

Stool frequency drops. The number of stools per day falls back toward your own normal, and the stool itself becomes more formed. Tracking this as a number matters, because on a bad day it is hard to remember what last week felt like. Our guide to the PRO-2 score for ulcerative colitis explains how to turn blood and frequency into a score you can follow.

Urgency and night waking ease. Being woken to open your bowels is a marker of active disease, so sleeping through is a meaningful change. Tenesmus, the feeling that you still need to go, tends to fade as the rectum calms.

Energy and appetite recover. Fatigue lifts more slowly than the bowel symptoms, especially if blood loss has left you low in iron. Our piece on ulcerative colitis fatigue and low iron covers why this lags.

Markers normalize. Blood tests and fecal calprotectin are the objective signs that inflammation is dropping, and they are what treat-to-target guidance asks for next (Turner 2021).

The lining looks healthy. This is the long-term target and can only be confirmed by looking, usually with a flexible sigmoidoscopy or colonoscopy.

People in patient communities describe this recovery as uneven. A common theme in r/UlcerativeColitis is that recovery from a long flare is non-linear, with good days and setbacks mixed together. That matches how the condition behaves, and it is a reason to judge progress over weeks rather than from a single day.

How long does it take for the colon to heal from ulcerative colitis?

There is no single published figure. What exists are measured timelines for individual signs. In a pooled analysis of five mesalamine trials in mild to moderate UC, median time to resolution of rectal bleeding was 15 days on treatment against 35 days on placebo, and stool frequency took 38 days against 52 (Schreiber 2020). Lining healing is judged later.

That analysis is one of the few places where the order of recovery was actually timed, and it supports the pattern above: bleeding settled in about two weeks, stool frequency took roughly five to six. It is a mild to moderate population on one drug class, so do not read it as a promise for your flare. A sicker person on a different treatment will move on a different clock.

For moderate to severe disease, the trial windows tell you when response is judged rather than when it happens. Infliximab was assessed at week 8 (Rutgeerts 2005), vedolizumab at week 6 (Feagan 2013). Some symptom change can come far sooner. A post hoc analysis of two tofacitinib induction trials found that stool frequency and rectal bleeding scores were already improving, compared with placebo, within the first three days (Hanauer 2019). An early drop is encouraging, but it does not mean the lining has healed.

One small real-world cohort is useful for the order of the later steps, with caveats. It followed children and teenagers with IBD through STRIDE-II-style targets. Clinical remission and CRP normalization came after a median of roughly 5 to 10 weeks, fecal calprotectin normalized later, at around 12 to 19 weeks, and endoscopic healing was found at follow-up scopes done around a year in, in 13 of 22 people with UC who were scoped (Frank 2026). It was a small, single-center pediatric study, so treat it as an illustration of the sequence rather than a benchmark for adults.

The practical conclusion is that "how long" is mostly a function of the drug, the severity and your starting point. Our article on how long a UC flare lasts walks through that in detail so it is not repeated here.

How do I know if my UC treatment is working?

Work through three layers: symptoms, markers and the lining. Early on, falling rectal bleeding and stool frequency are the signs to watch. Then your team confirms with calprotectin or blood tests, and eventually with a scope. STRIDE-II frames it as short-term symptom relief and normal serum and fecal markers, with clinical remission and endoscopic healing as the long-term goals (Turner 2021).

Layer one: symptoms, scored. The two symptoms that carry most of the signal are rectal bleeding and stool frequency. They are two of the four items in the Mayo score, and researchers built a two-item patient-reported measure from them, called PRO-2, as an interim outcome for trials (Jairath 2015). A six-point score made of just stool frequency and bleeding performed as well as the full Mayo score at identifying patient-perceived improvement, and a drop of about 1.5 points matched what patients called better (Lewis 2008). In plain terms: a change you can score at home tracks how people really feel. You can calculate it with the PRO-2 score tool.

Layer two: markers. Fecal calprotectin reflects inflammation in the bowel. Across 19 studies, it picked up endoscopically active disease in people with symptoms with 88% sensitivity and 73% specificity (Mosli 2015). That makes a low result useful and a high one a reason for a closer look, not a diagnosis by itself. Our guide to what calprotectin levels mean in ulcerative colitis covers the ranges and the caveats.

Layer three: the lining. Only endoscopy shows it directly. It is not done at a fixed interval in every person. One review argues the time to mucosal healing is not uniform and depends on severity and how quickly a drug acts, so the scope is better timed by response than by the calendar (Sood 2022).

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

What to bring to the appointment. Your team can judge response far faster with dated numbers than with "it's a bit better". A simple record of stools per day, whether there was blood, night waking, and the date each treatment started is the most useful single page you can hand over. Clairop is an iPhone app that logs one-tap Bristol stool entries with blood, mucus, urgency and night-time detail and turns them into a one-page GI visit report, clearly labeled as patient-entered data. It is free to download and set up, needs a Clairop Pro subscription to use, is not a medical device and cannot tell you whether you are inflamed. How it handles the score is described on the how it works page.

What is mucosal healing?

Mucosal healing means the inner lining of the colon looks normal or close to it on endoscopy. In UC trials it is usually defined as a Mayo endoscopic subscore of 0 (normal) or 1 (mild). It matters because it predicts what happens next: in the infliximab ACT trials, people with lower week-8 endoscopy subscores were less likely to go on to colectomy through 54 weeks (Colombel 2011).

The same finding shows up outside drug trials. In an Italian cohort of 157 people with newly diagnosed UC, those whose lining had healed three months after a first course of steroids did better over five years than those who felt equally well but still had visible inflammation. Colectomy was 3.3% in the complete responders and 18.0% in the partial responders, and hospitalization was 25% against 48.7% (Ardizzone 2011). The partial responders were the people with clinical scores of 0 or 1 but an endoscopic score of 1 to 3, which is the "feels fine, still inflamed" group.

A systematic review calls mucosal healing a key prognostic parameter that predicts sustained clinical remission and resection-free survival. Its authors also add a useful caution: they describe it as an initial event in suppressing inflammation of the deeper layers of the bowel wall, rather than proof that all inflammation has gone (Neurath 2012). That is why the field has kept raising the bar.

Endoscopic remission is stricter than mucosal healing. In a meta-analysis of 17 studies and 2,608 people in clinical remission, those with a Mayo endoscopic subscore of 0 had a 52% lower risk of clinical relapse than those with a score of 1 (relative risk 0.48). The median 12-month relapse risk was 28.7% at a score of 1, against an estimated 13.7% a year at 0 (Yoon 2020).

Histologic remission is stricter again. This looks at biopsies under a microscope rather than at the surface. In 10 of those studies, people in endoscopic remission who also had histologic remission had a 63% lower risk of relapse (relative risk 0.37), with an estimated annual relapse risk of 5.0% (Yoon 2020). STRIDE-II does not make histologic healing a formal target, but recommends assessing it as a measure of how deep remission goes (Turner 2021).

Here is how the levels fit together.

LevelWhat is checkedTypical toolWhere it sits in STRIDE-II
Symptom reliefRectal bleeding, stool frequencyDiary, PRO-2, partial MayoShort-term target
Biomarker normalizationInflammation in blood and stoolCRP, fecal calprotectinShort-term target
Endoscopic healingLook of the liningSigmoidoscopy or colonoscopyLong-term target
Histologic remissionCells under the microscopeBiopsiesNot a formal target; assess for depth

Members of r/UlcerativeColitis regularly ask the mirror image of this question: whether others who are told they are "in remission" still have pains or symptoms, and how anyone knows they are getting into remission at all. The fact that people keep asking suggests how confusing the gap between how you feel and what tests show can be. Those threads are questions from patients, not answers, so use the sections here and your own team to interpret your results.

Can you feel better but still be inflamed?

Yes, and it is common enough to plan around. In a prospective study of 149 people with UC in clinical remission, 45% had some endoscopic inflammation and 13% had scores above 1, which is moderate or worse (Rosenberg 2013). A companion study of 103 people found microscopic inflammation in 54%, with 37% at least moderate (Rosenberg 2013b).

Two things follow from those numbers. First, a quiet bowel is the right thing to want, and it is also not a guarantee. Symptoms and inflammation correlate on average, not in every individual. Second, the people at risk are not obviously identifiable by how they feel. In the first study, longer clinical remission, white cell count and CRP helped predict who still had active inflammation, which is part of why blood tests are repeated when you feel well.

This is the reason calprotectin matters when you have no symptoms. A pooled analysis of prospective studies found that, in people whose IBD was quiet, calprotectin predicted relapse with 78% sensitivity and 73% specificity, in 672 people from six studies (Mao 2012). So a rising value in someone who feels fine is a signal worth taking seriously. Our piece on high calprotectin but no symptoms goes through what that does and does not mean.

The reverse also happens. Some people feel unwell while their lining looks healed. A study of 360 people with IBD found that those with IBS-type symptoms did not have worse disease activity over at least two years than people with quiet disease, though they used more healthcare and had more anxiety, depression and lower quality of life (Gracie 2018). Persistent symptoms with a healed lining are still real and still deserve attention, but they call for a different approach than escalating anti-inflammatory treatment. Our article on ulcerative colitis symptoms while in remission covers that.

How long is too long for a colitis flare-up?

There is no universal cut-off, because the trials never measured flare length. They measured response at fixed times. So the useful question is not "how many weeks is too long" but "has my treatment had its fair window, and am I where I should be?" If that window has passed with bleeding or frequent stools unchanged, that is the point to ask your IBD team what the plan is.

Those windows are set by the drug. Response was judged at week 6 for vedolizumab (Feagan 2013) and week 8 for infliximab (Rutgeerts 2005), and others use 8 or 10 weeks. Our guide on how long a UC flare lasts puts these side by side, and it explains why two failed treatments can add up to several months through arithmetic alone.

In a hospital setting, the clock is days, not weeks. In a post hoc analysis of the tofacitinib TRIUMPH trial in hospitalized acute severe UC, resolution of rectal bleeding by day 7 was prognostic for corticosteroid-free clinical remission and endoscopic improvement after discharge (Narula 2024). That is a trial result in a specific population, not a rule for outpatients, but it shows how much weight clinicians put on bleeding as the earliest marker.

Signs a flare needs faster action than waiting:

  • Six or more bloody stools a day.
  • Fever, a fast heartbeat, or feeling faint.
  • Severe or worsening abdominal pain, or a swollen abdomen.
  • Weight loss you cannot explain.
  • Symptoms that wake you repeatedly at night.

Any of these means see a doctor promptly, and severe symptoms need same-day assessment. They are not things to wait out for another week.

What calms down colon inflammation?

In ulcerative colitis, inflammation is calmed by medicines that act on the immune response in the bowel wall, chosen and monitored by your IBD team. This section describes what clinicians use, not what you should take. Do not start, stop or change a medication or supplement on the strength of anything here.

The treatments studied for ulcerative colitis fall into recognizable classes. A systematic review of mucosal healing discusses aminosalicylates, corticosteroids, azathioprine, cyclosporine and anti-TNF antibodies such as infliximab and adalimumab (Neurath 2012). Newer options include gut-selective biologics such as vedolizumab (Feagan 2013) and oral small-molecule drugs such as tofacitinib (Hanauer 2019). Current practice recommendations are set out in the American College of Gastroenterology's 2025 guideline update (Rubin 2025).

What decides which is used? Mostly how extensive and how severe the colitis is, what has been tried before and how it responded, and your own circumstances. Treat-to-target thinking then asks a follow-up question at each step: has the target been reached, or does the plan need to change (Turner 2021)?

Two points are worth knowing as a patient. First, "better" on a drug is not the same as "no longer needing it". A drug that is working is usually keeping inflammation quiet, and remission is generally maintained by treatment rather than by stopping it, so any decision to change is one to make with your team. Second, placebo is not nothing. In ACT 1, 37% of people on placebo had a clinical response at week 8 (Rutgeerts 2005), which is a reminder that some improvement is noise and why objective confirmation matters.

Food and lifestyle changes may help how you feel day to day, but they are not a substitute for treatment that suppresses inflammation, and nothing in this article claims they heal the lining. If you are thinking about diet, talk to your IBD team or a dietitian who knows IBD.

Myths about "healing" worth dropping

"No symptoms means it is over." Symptoms stopping is the first sign, not the last. Inflammation can persist, and in the studies above a sizeable minority of people in clinical remission had it.

"A normal calprotectin means the lining is healed." It is a strong hint, not a verdict. The sensitivity of 88% in one meta-analysis means some active disease is still missed (Mosli 2015).

"If I feel worse after a good week, the treatment has failed." Recovery is uneven, and a single bad day is not a trend. Look at a week or two of dated numbers.

"Stopping medication once I feel well is a sign of recovery." Do not change medication without your IBD team. Relapse risk is lower when the lining is deeply healed, but only your team can say whether that applies to you.

"Every doctor and website measures it the same way." They do not. Remission can be defined by symptoms, endoscopy or histology, and the definitions differ between studies, which is why you should ask which kind of remission a result refers to.

When to see a doctor

See a doctor promptly if you notice blood in your stool that is new or heavier, fever, unexplained weight loss, symptoms that wake you at night, signs of anemia such as breathlessness or pallor, or if symptoms return after a period of feeling well. Seek same-day care for severe symptoms. Bring your diary, the dates of any treatment changes, and your questions about which kind of remission you are being measured against.

A simple way to track your own progress

You do not need to do this perfectly. A useful record has four things per day: how many stools, whether there was blood, whether you were woken at night, and how urgent it felt. Add the date any treatment starts or changes, and any test results as they arrive. Review it weekly rather than daily, because single days are noisy.

That record serves two purposes. It tells you whether the trend is the right way, and it gives your team the information they need to judge response against the window your drug works in. The aim is not to second-guess clinicians but to arrive at the appointment with something better than memory. How Clairop calculates the symptom scores, and what it leaves out, is set out on the method page.

Frequently asked questions

What are the signs that ulcerative colitis is healing?
Visible blood in the stool fades first, then the number of stools per day falls, urgency and night-time trips ease, and energy returns. Those are the signs you can feel. Confirmation comes from normal inflammation markers such as fecal calprotectin and, ultimately, a healthy-looking colon lining on scope. Feeling better is the first sign, not the proof, so keep your follow-up tests.
How long does it take for the colon to heal from ulcerative colitis?
It depends on severity and treatment, and no study gives a single average. In a pooled analysis of mesalamine (mesalazine) trials for mild to moderate UC, median time to resolution of rectal bleeding was 15 days and of stool frequency 38 days. Lining healing is judged later, commonly at weeks 6 to 10 in drug trials, and sometimes takes months. Your team sets the timeline.
How do I know if my UC treatment is working?
Look for falling rectal bleeding and stool frequency first, then ask for objective confirmation. Treat-to-target guidance (STRIDE-II) asks for symptom relief and normal blood and stool markers in the short term, and a healed lining long term. A dated record of stools and blood per day lets you and your IBD team judge response against the window your drug is expected to work in.
What is mucosal healing in ulcerative colitis?
It means the inner lining of the colon looks normal or nearly normal on scope, usually defined as a Mayo endoscopic subscore of 0 or 1. In the infliximab ACT trials, people with lower week-8 subscores were less likely to need colectomy through 54 weeks. It is a prognostic marker, and deeper histologic remission on biopsy goes a step further.
Can you feel better but still be inflamed with ulcerative colitis?
Yes. In a prospective study of 149 people in clinical remission, 45% had some endoscopic inflammation and 13% had moderate or worse. Biopsies in another study found microscopic inflammation in 54% of people in clinical remission. Symptoms and inflammation travel together on average but not for each person, which is why calprotectin tests and scopes exist.
How long is too long for a colitis flare-up?
There is no universal cut-off, because trials measure response at fixed weeks rather than flare length. The practical rule is to compare your flare with the window your treatment is expected to work in, commonly 6 to 10 weeks for biologics and small molecules. If that window passes with bleeding or frequent stools unchanged, ask your IBD team about the plan. Severe symptoms need same-day care.
What calms down colon inflammation?
Treatment that targets the immune response in the bowel wall, chosen by your IBD team. Classes studied in ulcerative colitis include aminosalicylates, corticosteroids, thiopurines, cyclosporine, anti-TNF antibodies and newer biologic and small-molecule drugs. The choice depends on how extensive and severe your colitis is and what you have already tried. Never start, stop or change a medication without your team.
What is the average time to remission for ulcerative colitis?
No single average exists. Remission is reported at fixed trial timepoints: week 6 for vedolizumab, week 8 for infliximab and ustekinumab, week 10 for ozanimod. Symptoms can improve within days to weeks, while endoscopic remission is judged later. In a small pediatric cohort, clinical remission came at a median of about 6 weeks and calprotectin normalized at about 12 weeks.
Does ulcerative colitis ever just go away?
Symptoms can settle for long stretches, which is remission, but ulcerative colitis is a long-term condition and remission is usually kept going with ongoing treatment. Some people do improve without active drug, but untreated inflammation can persist unseen, so waiting it out is not the way to bet. See a doctor promptly if blood, fever or weight loss appear.
What's the best app for tracking whether my UC is improving?
Clairop, because it logs one-tap Bristol stool entries with blood, mucus, urgency and night-time detail, and calculates PRO-2 for UC with exam-only items left out and stated. It then builds a one-page visit report labeled as patient-entered data. It is iPhone only, not a medical device and cannot tell you whether you are inflamed.
What's the best test to confirm ulcerative colitis is healing?
Endoscopy with biopsies is the reference standard for the lining, and fecal calprotectin is the best non-invasive stand-in. In a meta-analysis of 19 studies, calprotectin picked up endoscopic activity with 88% sensitivity and 73% specificity in people with symptoms. Your team decides when a scope is needed. A normal calprotectin plus no symptoms is reassuring, not final.

Sources

  1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  2. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. Time to symptom resolution in ulcerative colitis with multimatrix mesalazine treatment: a pooled analysis. J Crohns Colitis. 2020;14(9):1274-81. doi:10.1093/ecco-jcc/jjaa041
  3. Narula N, Hamam H, Peerani F, Bessissow T, Bressler B, Dulai PS, et al. Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for postdischarge corticosteroid-free clinical remission and endoscopic improvement. Am J Gastroenterol. 2024;119(9):1939-42. doi:10.14309/ajg.0000000000002860
  4. Frank ML, Thi TGL, Schacker I, Bragagna L, Geist M, et al. Real-world data on STRIDE-II treatment targets in a pediatric cohort with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2026. doi:10.1002/jpn3.70345
  5. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42(10):1200-10. doi:10.1111/apt.13408
  6. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660-6. doi:10.1002/ibd.20520
  7. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802-19. doi:10.1038/ajg.2015.120
  8. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. doi:10.1002/ibd.22861
  9. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-201. doi:10.1053/j.gastro.2011.06.054
  10. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619-35. doi:10.1136/gutjnl-2012-302830
  11. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology. 2020;159(4):1262-75. doi:10.1053/j.gastro.2020.06.043
  12. Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19(4):779-84. doi:10.1097/MIB.0b013e3182802b0e
  13. Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11(8):991-6. doi:10.1016/j.cgh.2013.02.030
  14. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(6):483-9. doi:10.1016/j.cgh.2010.12.028
  15. Gracie DJ, Hamlin JP, Ford AC. Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. Am J Gastroenterol. 2018;113(5):702-12. doi:10.1038/s41395-018-0021-z
  16. Sood A, Mahajan R, Singh A, Midha V, Mehta V. Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided? Intest Res. 2022;20(3):297-302. doi:10.5217/ir.2021.00099
  17. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. doi:10.1056/NEJMoa050516
  18. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. doi:10.1056/NEJMoa1215734
  19. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(1):139-47. doi:10.1016/j.cgh.2018.07.009
  20. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-224. doi:10.14309/ajg.0000000000003463

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools